<DOC>
	<DOCNO>NCT00874744</DOCNO>
	<brief_summary>The purpose study compare single intravitreal injection 4.0 mg triamcinolone acetonide 1.25 mg bevacizumab treatment diabetic macular edema .</brief_summary>
	<brief_title>Comparison Single Intravitreal Injection Triamcinolone Bevacizumab Treatment Diabetic Macular Edema</brief_title>
	<detailed_description>Comparison single intravitreal injection 4.0 mg triamcinolone acetonide 1.25 mg bevacizumab regard ability central macular thickness reduction . Secondary objective analysis Visual Outcomes variation Intraocular Pressure . The patient data statistically analyze 24 week follow complete .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Diabetic macular edema central foveal measurement 300 micrometer Glaucoma Vitreoretinal surgery Cataract Surgery le 3 month prior inclusion Unilateral cataract surgery Uncontrolled Glycosylated Hemoglobin Previous Intraocular Injection Systemic Corticosteroids less 1 month prior inclusion Macular ischemia Fluorescein Angiography Cataract preclude fundus examination Active Proliferative Diabetic Retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Diabetic macular edema</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>Pharmacological treatment</keyword>
</DOC>